Type of expressed molecule | Whole Lt and/or purified protein | Expressed molecule | Target infection/disease | Animal model | Selected references |
---|---|---|---|---|---|
WT | Whole Lt | // | Leishmaniasis | Murine | |
GM for: GFP | Whole Lt | GFP to trace Leishmania tarentolae | Leishmaniasis | Murine | [41] |
GM for: pLs prot | Whole Lt and/or purified protein | pLs A2 antigen pLs A2 antigen + cysteine proteinases A and B (CPA and CPB without C terminal extension) pLs Leishmania homolog of the receptor for the activated C kinase (LACK) + pLs kinetoplastida membrane protein-11 (KMP11) Leishmania infantum lipophosphoglycan 3 (LPG3) pLs cysteine proteinases A and B (CPA, CPB) | Leishmaniasis | Murine Hamster | |
GM for: IM prot | Whole Lt | Interferon-gamma-induced protein 10 (IP-10) or CXCL-10 Human neutrophil peptide-1 (HNP-1) Immunogenic Phlebotomus papatasi salivary molecule SP15 (PpSP15) Immunogenic Ph. papatasi salivary molecule SP15 (PpSP15) + Phlebotomus sergentii salivary molecule SP9 (PsSP9) | Leishmaniasis | Murine | |
GM for: IM prot + pLs prot | Whole Lt | pLs kinetoplastida membrane protein-11 (KMP11) + N-terminal domain of heat shock protein GP96 (NT-GP96) | Leishmaniasis | Murine | [108] |
GM for: other protozoan protein | Whole Lt and/or purified protein | Fusion of immunodominant epitopes of 5 Toxoplasma antigens: SAG1-ROP16-GRA12-MIC4-M2AP | Toxoplasmosis | Murine | [99] |
GM for: viral protein | Whole Lt and/or purified protein | HPV16-L1 SARS-CoV-2 spike protein/RBD HIV-1 Gag HCV envelope glycoproteins (HCV E1-E2) | HPV SARS-CoV-2 HIV HCV | Murine Human tissue | |
GM for: IM prot + viral protein | Whole Lt and/or purified protein | HCV polytope (PT) fused to the N-terminal domain of heat shock protein GP96 (HCV-PT + NT-GP96) (HPV-E7 + NT-GP96) + (HPV-E7 + CT-GP96) | HPV HCV | Murine | |
GM for: VLPs | VLPs | HPV late protein 1 (HPV16 L1) HBV small surface antigen (sHBsAg) presenting epitopes derived from the HCV E2 glycoprotein NoV Capsid Prot | HPV HBV HCV NoV | Murine |